Stockreport

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized [Yahoo! Finance]

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month median overall survival in heavily pretreated microsatellite stable (MSS) metastatic [Read more]